Guidance for Blueprint Medicines (BPMC)
| Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
|---|---|---|---|---|---|---|
| 2025 | N/A | N/A | $700.00M – 720.00M | $723.20M | = Maintained | Details |
| 2025 | N/A | N/A | $680.00M – 710.00M | $726.20M | = Maintained | Details |
| 2024 | N/A | N/A | $475.00M – 480.00M | $497.30M | = Maintained | Details |
| 2024 | N/A | N/A | $435.00M – 450.00M | $434.90M | = Maintained | Details |
| 2024 | N/A | N/A | $390.00M – 410.00M | $393.00M | = Maintained | Details |
| 2024 | N/A | N/A | $360.00M – 390.00M | $391.00M | = Maintained | Details |
| Q3 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q2 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q1 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q4 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q3 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q2 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q1 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
